Clinicians Trial brief

TOGETHER-PsA: obesity & joint health

Originally posted Jan 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 719 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

A visual readout of tirzepatide plus ixekizumab in psoriatic arthritis and obesity.

Yesterday’s data from Eli Lilly regarding Zepbound suggests a new direction in how we approach the dual burden of Psoriatic Arthritis (PsA) and obesity.

The Phase 3b TOGETHER-PsA trial is the first controlled study to show that adding an incretin therapy to a biologic like Taltz does not just manage weight. It significantly improves the arthritis treatment response.

As highlighted in my infographic, the results are strong.

- The Primary Endpoint (Double Win): Nearly 32% of patients on combination therapy achieved both ACR50 clearance and greater than 10% weight loss at 36 weeks, compared to less than 1% on monotherapy.

- Improved Joint Response: Even when looking strictly at arthritis scores, adding tirzepatide resulted in a 64% relative increase in patients responding to the biologic.

For our patients living with both chronic inflammatory disease and adiposity, this data suggests that managing metabolic health acts as a disease-modifying factor for their arthritis.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

TOGETHER-PsA: obesity & joint health

Pinch to zoom on touch devices. Open full image ↗